Microsoft word - 81-84
TOWARDS DEFINING CRITERIA FOR METFORMIN USAGE IN
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS
Hamidreza Mahboobi1, 2, Tahereh Khorgoei3, Aida Najafian1
1: Reproductive Health Research Center, Hormozgan University of Medical Sciences (HUMS), BandarAbbas, Iran2: Payame Noor University (PNU), Iran3: Hormozgan Cardiovascular Research Center, Hormozgan University of Medical Sciences (HUMS),Bandar Abbas, Iran
Hamidreza Mahboobi, Hormozgan University of Medical Sciences (HUMS), Bandar Abbas, Iran. Phone:
+ 98. 9364300250, E-mail: [email protected]
Bibliographic information of this paper for citing:
Hamidreza Mahoobi, Tahereh Khorgoei, and Aida Najafian. Towards defining criteria for
metformin usage in management of Gestational Diabetes Mellitus. Electron. Pysicician 2010, 2:81-84,
Available at: http://www.ephysician.ir/2010/81-84.pdf
Received: 26 June 2010Revised: 03 July 2010Accepted: 05 July 2010Published: 07 July 2010 2009-2010 Electronic Physician
Gestational diabetes mellitus; Metformin
(2). Without treatment, GDM is associatedwith
complications (3). Insulin is commonly used
pregnancies (1), and pregnancy outcomes in
glycemic control with medical nutritional
GDM are strongly related to glucose control
lowering the blood glucose as well as being
teratogenic, and did not adversely affect
birth length and weight, growth, or motor
social development in the first 18 months of
educating with regard to insulin injection
before they start using it, and there is alsoalways a chance of hypoglycemia in these
Although metformin seems to be as effective
patients. Moreover, insulin resistance and
as insulin in management of patients with
insulin, there are still concerns about its
safety in neonates. Randomized controlled
have lead to increasing interest for the usage
trials assessing metformin safety in neonates
of oral hypoglycemic agents in the treatment
and long-term follow-up of these neonates is
lacking. Insulin is still the drug of choice in
oral agents are easier to administer than
up of metformin effects on neonates could
insulin in clinical practice (11). However,
change this role and may revolutionize the
there are concerns that oral agents can cross
should consider that specific patients such as
teratogenesis and other fetal complications,
resistance (24) may benefit more than others
resistance, remains unclear (7, 12).
should be carried out on specific patients in
induction of ovulation in PCOS patients (13)
and is associated with a reduction ingestational
pharmacokinetics of metformin in pregnantwomen is similar to those in non-pregnant
patients (12). Metformin was found to bereadily transferable from the maternal tofetal circuits across placentas that were
Epidemiology of gestational diabetes mellitus
and its association with Type 2 diabetes.
study showed that preeclampsia and prenatal
Diabetic Medicine. 2004;21(2):103-13.
mortality are more common in patients who
were treated with metformin in comparison
HD. Glycemia and its relationship to outcomes
in the metformin in gestational diabetes trial.
these findings (21). Potential hypoglycemicagents have been shown to have no adverse
3. Langer O, Yogev Y, Most O, Xenakis EMJ.
Gestational diabetes: The consequences of not
have additional benefits, including reducing
treating. American Journal of Obstetrics and
insulin resistance, body weight, long term
risk of diabetes (23), and development of
4. Gestational Diabetes Mellitus. Diabetes Care.
2004 January 2004;27(suppl 1):s88-s90.
throughout pregnancy reduces the development
Jovanovic L. Comparison of an insulin analog,
of gestational diabetes in women with polycystic
insulin aspart, and regular human insulin with no
insulin in gestational diabetes mellitus. Diabetes
15. Stadtmauer LA, Wong BC, Oehninger S.
6. Jovanovic L, Ilic S, Pettitt DJ, Hugo K,
Should patients with polycystic ovary syndrome
Gutierrez M, Bowsher RR, et al. Metabolic and
be treated with metformin? Benefits of insulin
sensitizing drugs in polycystic ovary syndrome--
beyond ovulation induction. Hum Reprod. 2002
7. Homko CJ, Sivan E, Reece AE. Is there a role
16. Glueck CJ, Wang P, Goldenberg N, Sieve-
diabetes and type 2 diabetes during pregnancy?
with polycystic ovary syndrome treated with
8. Catalano PM, Kirwan JP, Haugel-de MouzonS, King J. Gestational Diabetes and Insulin
Loftspring M, Sherman A. Metformin during
Implications for Mother and Fetus. J Nutr. 2003
pregnancy reduces insulin, insulin resistance,
development of gestational diabetes: prospective
hypoglycemic agents in pregnancy. J Matern
polycystic ovary syndrome from preconception
Fetal Neonatal Med. 2006 Nov;19(11):679-86.
10. Rowan JA, Hague WM, Gao W, Battin MR,Moore MP. Metformin versus insulin for the
18. Glueck CJ, Goldenberg N, Pranikoff J,
treatment of gestational diabetes. N Engl J Med.
Loftspring M, Sieve L, Wang P. Height, weight,
and motor-social development during the first 18months of life in 126 infants born to 109
11. Carles G, Germain L, Alassas N, El Guindi
mothers with polycystic ovary syndrome who
conceived on and continued metformin through
gestational diabetes with oral hypoglycemic
pregnancy. Hum Reprod. 2004 Jun;19(6):1323-
agents]. J Gynecol Obstet Biol Reprod (Paris).
19. Nanovskaya TN, Nekhayeva IA, Patrikeeva
12. Charles B, Norris R, Xiao X, Hague W.
Population pharmacokinetics of metformin in
metformin across the dually perfused human
placental lobule. Am J Obstet Gynecol. 2006
20. Hellmuth E, Damm P, Molsted-Pedersen L.
Rotmensch S, Glezerman M. Neonatal outcome
Oral hypoglycaemic agents in 118 diabetic
in polycystic ovarian syndrome patients treated
pregnancies. Diabet Med. 2000 Jul;17(7):507-
with metformin during pregnancy. J Matern
Fetal Neonatal Med. 2006 Jul;19(7):415-9.
14. Glueck CJ, Wang P, Kobayashi S, Phillips
outcomes in women with polycystic ovarysyndrome. Diabet Med. 2004 Aug;21(8):829-36.
Diagnosis and new approaches in the therapy ofgestational diabetes mellitus. Curr Diabetes Rev.
23. Hawthorne G. Metformin use and diabeticpregnancy-has its time come? Diabet Med. 2006Mar;23(3):223-7.
24. Simmons D, Walters BN, Rowan JA,McIntyre HD. Metformin therapy and diabetesin
Updates to your prescription benefits Effective January 1, 2013 Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill a prescription. Please reference this chart as you review the following updates. Most options listed are available in Tier 1, your lowest cost option. If your medication is listed below,
Assessment of Resilience in the Aftermath of Trauma Kathryn M. Connor, M.D. Resilience is a crucial component in determining the way in which individuals react to and dealwith stress. A broad range of features is associated with resilience; these features relate to thestrengths and positive aspects of an individual’s mental state. In patients with posttraumatic stress dis-order, resilienc